Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
F&G: 63
6.487,50 S&P · 15,58 Vola-Index · 119.095,11 BTC · 1,16834 EURUSD
System-State: Number of processed items 55.061 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
AGP8696W1045
State: 15.08.2025 | 11AM
Do you already know our new terminal view? Click here.
FIGI: BBG000D0D8P5
SVA
Sinovac Biotech Ltd
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
NAME
Sinovac Biotech Ltd
ISIN
AGP8696W1045
TICKER
SVA
MIC
XNAS
REUTERS
SVA.OQ
BLOOMBERG
SVA US
Thu, 10.07.2025       Sinovac Bio
AGP8696W1045

Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan an...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Wed, 09.07.2025       Sinovac Bio
AGP8696W1045

SAIF Partners IV L.P., (“SAIF Partners”, “we” or “us”), today announced that Sinovac Biotech Ltd. (“Sinovac” or the “Company”) shareholders voted to approve SAIF Partners’ proposals to remove the Company’s incumbent directors and to elect SAIF Partners’ slate of ten highly qualified director nominees to the Board of Directors (the “Board”) at Sino...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Wed, 09.07.2025       Sinovac Bio
AGP8696W1045

Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today announced that the Court of Appeals of the Eastern Caribbean Supreme Court granted a motion to stay the self-interested injunction s...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Wed, 02.07.2025       Sinovac Bio
AGP8696W1045

Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long-term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today announced that the United States District Court of Massachusetts (“the Court”) granted Vivo’s motion for a preliminary injunction ag...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Wed, 02.07.2025       Sinovac Bio
AGP8696W1045

Third paragraph, second sentence of release should read: These include the current Board’s failure to actively engage with management, its lack of sound financial reasoning for its proposed dividend figures, its apparent unwillingness to hire a new independent auditor after it drove Sinovac’s prior public accounting firm to resign in April, and it...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Wed, 02.07.2025       Sinovac Bio
AGP8696W1045

SAIF Partners IV L.P., (“SAIF Partners”, “we” or “us”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”) which beneficially owns approximately 15% of the Company’s outstanding common shares, today urged shareholders to immediately vote “FOR” the election of SAIF Partners’ ten highly qualified director candidates to ...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Tue, 01.07.2025       Sinovac Bio
AGP8696W1045

SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to Sinovac shareholders regarding the current Board’s empty promises to shareholders, numerous failures overseeing the Company, and c...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Tue, 24.06.2025       Sinovac Bio
AGP8696W1045

SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to its fellow Sinovac shareholders exposing the current Sinovac Board’s failure to act in the interest of all shareholders resulting ...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Sun, 22.06.2025       Sinovac Bio
AGP8696W1045

Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued a statement in response to the decision by the United States District Court for the Southern D...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Wed, 18.06.2025       Sinovac Bio
AGP8696W1045

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the “Board”) and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nomin...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Tue, 17.06.2025       Sinovac Bio
AGP8696W1045

Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued a statement in response to the Company’s continued false, misleading and outright fabricated c...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Mon, 16.06.2025       Sinovac Bio
AGP8696W1045

SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today announced that it has filed a definitive proxy statement for the election of ten director nominees to Sinovac’s Board of Directors (the “Board”) in...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Mon, 16.06.2025       Sinovac Bio
AGP8696W1045

The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today disclosed that on June 12, 2025, Advantech/Prime Success filed a Petition for Emergency Injunctive Relief against SINOVAC, et al., naming as relief parties Cede & Co., The Depository Trust ...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Sat, 14.06.2025       Sinovac Bio
AGP8696W1045

Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued the following letter in response to the Company’s recent false and misleading claims relating ...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Fri, 13.06.2025       Sinovac Bio
AGP8696W1045

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it intends to file its definitive proxy materials in the coming days with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Wed, 11.06.2025       Sinovac Bio
AGP8696W1045

Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and an approximately 8% shareholder in Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today sent a letter to shareholders. *** Dear Fellow Sinovac Shareholders, We, Vivo Capital (“Vivo”), write to you as fellow...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Wed, 11.06.2025       Sinovac Bio
AGP8696W1045

Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued a letter to shareholders in connection with the upcoming Special Meeting of Shareholders (the ...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Fri, 23.05.2025       Sinovac Bio
AGP8696W1045

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 16, 2025 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq Listing Rule 5250...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Wed, 30.04.2025       Sinovac Bio
AGP8696W1045

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, ET....
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Tue, 29.04.2025       Sinovac Bio
AGP8696W1045

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) issued a public letter to shareholders in response to hostile actions and false claims by Vivo Capital and certain other parties (the “Vivo group”) against the legitim...
Read More
Sinovac Bio
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Sensorion
Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux
© BusinessWire
Accenture
Accenture to Acquire CyberCX, Expanding Cybersecurity Capabilities in Asia Pacific
© BusinessWire
Intercontinental Exchange
ICE Index Serves as Benchmark for Taiwan’s First Multi-Asset ETF Issued by KGI SITE
© BusinessWire
ReShape Lifesciences
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
© BusinessWire
Accord Financial Corp.
Accord Announces Second Quarter Financial Results
© BusinessWire
FRMO
FRMO Corp. Announces Fiscal 2025 Results and Annual Meeting
© BusinessWire
Circle Internet
Circle Announces Pricing of Public Offering
© BusinessWire
Bolt Projects
Bolt Projects Announces $4.25 Million Private Placement
© BusinessWire
Liberty All-Star Growth
Liberty All-Star® Growth Fund, Inc. July 2025 Monthly Update
© BusinessWire
Liberty All-Star Equity Fund
Liberty All-Star® Equity Fund July 2025 Monthly Update
© BusinessWire
Celanese
Securities Fraud Investigation Into Celanese Corporation (CE) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
© BusinessWire
Chemtrade Logistics Income Fund
Chemtrade Announces Strong Results for Q2 2025, Raises Guidance for 2025 to $475M - $500M; Implementing New NCIB & Redeeming Convertible Debentures
© BusinessWire
NU Holdings
Nu Holdings Ltd. Reports Second Quarter 2025 Financial Results
© BusinessWire
SmartStop Self Storage
SmartStop Self Storage REIT, Inc. Highlights AI Strategy at Ai4 2025, North America’s Leading Artificial Intelligence Conference
© BusinessWire
Almonty Industries
Almonty Industries Reports Second Quarter 2025 Financial Results
© BusinessWire
Drive Shack
Drive Shack Inc. Issues Quarterly Financial Statements for Second Quarter 2025
© BusinessWire
Carter's
Carter’s, Inc. Announces Quarterly Dividend
© BusinessWire
SIFCO Industries
SIFCO Industries, Inc. (“SIFCO”) Announces Third Quarter and First Nine Months of Fiscal 2025 Financial Results
© BusinessWire
Lithium Royalty
Lithium Royalty Corp. Announces Second Quarter 2025 Results
© BusinessWire
ATS Corporation
ATS to Participate in the Jefferies Industrials Conference
© BusinessWire
JanOne
ALT5 Sigma Corporation Appoints Jonathan Hugh as CFO
© BusinessWire
Chemtrade Logistics Income Fund
Chemtrade Logistics Income Fund to Acquire Polytec, a Provider of Turnkey Water Treatment Solutions
© BusinessWire
ATS Corporation
ATS to Participate in the RBC Capital Markets Global Industrials Conference
© BusinessWire
American Water Works
California Public Utilities Commission Approves Water Supply Decision Supporting California American Water's Monterey Peninsula Desalination Project
© BusinessWire
Medical Properties Trust
Medical Properties Trust Declares Regular Quarterly Dividend
© BusinessWire

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.

 

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S